As Bristol Myers Squibb Co (BMY) Stock Declined, Chesley Taft & Associates LLC Increased Position by $6.68 Million

February 24, 2018 - By Maria Brooks

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Investment Management Of Virginia Ltd Liability Co has 28,889 shares for 0.43% of their portfolio. Engineers Gate Manager Limited Partnership reported 38,553 shares stake. Saturna Corporation invested in 684,513 shares. Marco Investment Mngmt Ltd reported 0.28% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Foster Dykema Cabot Company Ma has 0.12% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 10,595 shares. Metropolitan Life Insurance Comm Ny invested 0.32% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Folger Nolan Fleming Douglas Cap Management stated it has 17,223 shares. Legacy Private Trust reported 0.15% stake. Manchester Cap Ltd Limited Liability Company has invested 0.08% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Oregon Public Employees Retirement Fund has invested 0.41% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Fic Cap Inc invested in 0.21% or 8,740 shares. Dowling Yahnke Ltd owns 102,331 shares. North Carolina-based Saybrook Nc has invested 0.48% in Bristol-Myers Squibb Company (NYSE:BMY). Chem Bancorporation holds 0.29% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 41,033 shares. Modera Wealth Mngmt Limited Liability reported 5,228 shares or 0.08% of all its holdings.

Since September 6, 2017, it had 1 insider purchase, and 2 sales for $646,385 activity. Shares for $335,172 were sold by Lynch Thomas J. Jr.. Caldarella Joseph C sold 9,340 shares worth $560,400.

Chesley Taft & Associates Llc increased its stake in Bristol Myers Squibb Co (BMY) by 1385.62% based on its latest 2017Q3 regulatory filing with the SEC. Chesley Taft & Associates Llc bought 106,000 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 113,650 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $7.24 million, up from 7,650 at the end of the previous reported quarter. Chesley Taft & Associates Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $110.93 billion market cap company. The stock increased 3.05% or $2.01 during the last trading session, reaching $67.95. About 5.24 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 24, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Bloomberg.com which released: “Nektar Gets a Payday But No Mega-Buyout” on February 14, 2018, also Seekingalpha.com with their article: “Nektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails” published on February 15, 2018, Fool.com published: “Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?” on February 20, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Bristol-Myers Squibb Makes Enormous Advance In First-Line Lung Cancer” published on February 06, 2018 as well as Thestreet.com‘s news article titled: “3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb” with publication date: February 16, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. SunTrust upgraded the shares of BMY in report on Monday, October 30 to “Buy” rating. As per Tuesday, June 14, the company rating was maintained by Jefferies. The firm has “Buy” rating by UBS given on Friday, April 29. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Buy” rating given on Wednesday, October 18 by Citigroup. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Sell” rating by BMO Capital Markets on Sunday, July 23. Credit Suisse maintained Bristol-Myers Squibb Company (NYSE:BMY) on Wednesday, August 16 with “Hold” rating. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Monday, October 16. Citigroup maintained it with “Buy” rating and $78.0 target in Friday, February 16 report. The firm earned “Market Perform” rating on Monday, January 25 by BMO Capital Markets. Hilliard Lyons downgraded it to “Hold” rating and $65.0 target in Tuesday, September 12 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: